Related Experiment Videos

Role of Adiponectin in Coronary Heart Disease Risk: A Mendelian Randomization Study

Maria Carolina Borges1, Debbie A Lawlor2, Cesar de Oliveira2

  • 1From the Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Brazil (M.C.B., B.L.H., A.J.D.B.); MRC Integrative Epidemiology Unit (D.A.L.); School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom (D.A.L.); and Epidemiology and Public Health, Institute of Epidemiology and Health Care (C.d.O.) and UCL Genetics Institute, Division of Biosciences, Faculty of Life Sciences (J.W.), University College London, London, United Kingdom. carolina.borges.mcb@gmail.com.

Circulation Research
|June 3, 2016
PubMed

Insights

This study investigated the causal link between adiponectin levels and coronary heart disease (CHD). Findings suggest adiponectin does not play a causal role in CHD development.

Area of Science:

  • Cardiovascular disease research
  • Metabolic disorders
  • Genetic epidemiology

Background:

  • Hypoadiponectinemia is linked to coronary heart disease (CHD) risk factors.
  • The direct causal role of adiponectin in CHD pathogenesis remains unclear.

Purpose of the Study:

  • To investigate the potential causal effect of adiponectin on the risk of developing CHD.
  • Utilizing Mendelian randomization to assess adiponectin's etiological role in CHD.

Main Methods:

  • A Mendelian randomization study was conducted using large-scale genome-wide association study consortia data.
  • Genetic variants associated with adiponectin levels served as instrumental variables.
  • Data from CARDIoGRAM and CARDIoGRAMplusC4D Metabochip consortia were used to assess the association with CHD risk.

Main Results:

  • In a conservative analysis, increased adiponectin levels showed a trend towards reduced CHD odds, but results were not statistically significant (OR 0.83-0.97).
  • A broader analysis (liberal approach) suggested a protective effect that became non-significant after accounting for known CHD risk predictors.
  • The association between adiponectin and CHD risk was not consistently supported across analyses.

Conclusions:

  • The current findings do not provide evidence for a causal relationship between adiponectin levels and the pathogenesis of coronary heart disease.
  • Adiponectin's role in CHD may be observational rather than causal, influenced by other risk factors.
Abstract

Keywords:
adiponectincardiovascular diseasecoronary artery diseasemendelian randomization analysis obesity

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
817
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
915
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
569
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75